Pimavanserin, a 5-HT2A serotonin receptor blocker, is the only antipsychotic without D2R antagonistic properties, but it failed in schizophrenia trials and is currently approved only for Parkinson’s disease psychosis [15]. The gene discussed is DRD2; the disease is schizophrenia.